Nature Cell said Monday that it has injected 10 doses of Astrostem, a stem-cell therapy for Alzheimer's disease, to the initial patient participating in its phase 2 clinical trials in the U.S.
Astrostem is the world's first intravenous Alzheimer's disease stem-cell therapy developed by Nature Cell and Biostar. It is administered 10 times intravenously every two weeks. Each dose contains 200 million cells.
Six patients are currently participating in the clinical trials, and no significant adverse events or side effects have appeared during the clinical trials so far.
“Stem-cell clinical trials that are ongoing for Alzheimer's are obviously groundbreaking and innovative,” said Gustavo Alva, medical director at ATP Clinical Research. “The company is very excited to see the potential of the fusion between technology and science for the treatment of serious neurodegenerative diseases such as Alzheimer's disease.”
Nature Cell also showed enthusiasm for the clinical trials.
“The company plans to apply for clinical trials in Korea by the end of this year after adding the safety data of the four patients participating in the U.S. clinical trials, ” said Ra Jeong-chan 라정찬, CEO of Nature Cell 네이처셀 and Biostar 바이오스타. “The company expects to finish both clinical trials in the U.S. and Korea by the end of next year.”